Asprin And Extended-release Dipyridamole recalls
Asprin And Extended-release Dipyridamole products have been recalled 1 time, most recently on 27 Jul 2022. The recalling company is usually Glenmark Pharmaceuticals Inc., USA.
Total recalls1since 2022
Last 12 months0reported
Class I00% of total
Ongoing1latest 27 Jul 2022
Recalls per month, last 24 months
click a bar for that monthSeverity split
Class I 0 0%Class II 0 0%Class III 1 100%
Why asprin and extended-release dipyridamole is recalled
Companies
Product types
By year
Ongoing asprin and extended-release dipyridamole recalls
1 active| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg recalledAsprin And Extended-release Dipyridamole | Glenmark Pharmaceuticals Inc., USA | Other | Nationwide |
All asprin and extended-release dipyridamole recalls, newest first
1 total| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Aspirin and Extended-Release Dipyridamole Capsules, 25mg/200 mg recalledAsprin And Extended-release Dipyridamole | Glenmark Pharmaceuticals Inc., USA | Other | Nationwide |
About this list
Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.